Previous 10 | Next 10 |
Navidea Biopharma (NYSE:NAVB) stock rose +16.3% post market after it said India approved its Lymphoaim imaging (Tc99m tilmanocept) in patients with breast cancer, melanoma, or localized squamous cell carcinoma of the oral cavity. Tc99m tilmanocept is designed to ...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the regulatory approval of Lymphoaim (“Lymphoseek...
Navidea Biopharmaceuticals (NYSE:NAVB) shares surged 12% during Tuesday extended trading on receipt of an acceptance letter from the NYSE American. The biopharmaceutical company company received a notification from the NYSE American back in Jan stating that it was not in compliance ...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors has adopted a Section 382 Rights...
As previously disclosed, on January 28, 2022, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received a notification from t...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today welcomed Kenneth Berger, Ph.D., as Senior Regulatory Consultant, and t...
Navidea (NAVB -13.0%) stock declined after Q4 revenue declined -77.04% Y/Y to ~$50K. FY21 revenue decreased -41.91% Y/Y to $0.53M. The company said the decline was mainly due to decreased grant revenue from the National Institutes of Health supporting Manocept development and fall in royalty ...
Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2021 Earnings Conference Call March 23, 2022 17:00 ET Company Participants Michael Rosol - Chief Medical Officer Erika Eves - Vice President, Finance and Administration Conference Call Participants Edward English - Private Investor Presentation Opera...
Conference Call to be held Wednesday, March 23, 2022 at 5:00 pm (EST) This press release is being re-issued to revise the language in the Selling, General and Administrative bullet under Financial Results. That third bullet, third sentence should read: The net increase durin...
Navidea Biopharm press release (NYSE:NAVB): Q4 GAAP EPS of -$0.12. Revenue of $0.05M (-77.3% Y/Y). cash and cash equivalents of $4.2M For further details see: Navidea Biopharm GAAP EPS of -$0.12, revenue of $0.05M
News, Short Squeeze, Breakout and More Instantly...
Navidea Biopharmaceuticals Inc. Company Name:
NAVB Stock Symbol:
NYSE Market:
Navidea Biopharmaceuticals Inc. Website:
Navidea Biopharmaceuticals , Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic a...
Navidea Biopharmaceucitals, Inc. will present two proposals for vote in a virtual special meeting of shareholders to be held on July 8, 2024 Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of pre...
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the &...